Log in
Enquire now
‌

US Patent 11851655 Compositions and methods for modulating apolipoprotein (a) expression

Patent 11851655 was granted and assigned to Ionis Pharmaceuticals on December, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Ionis Pharmaceuticals
Ionis Pharmaceuticals
0
Current Assignee
Ionis Pharmaceuticals
Ionis Pharmaceuticals
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
118516550
Patent Inventor Names
Eric E. Swayze0
Mark J. Graham0
Punit P. Seth0
Thazha P. Prakash0
Date of Patent
December 26, 2023
0
Patent Application Number
170604400
Date Filed
October 1, 2020
0
Patent Citations
‌
US Patent 7262177 Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use
0
‌
US Patent 7267819 Composition comprising and method of using angiopoietin-like protein 3 Angptl3
0
‌
US Patent 7399845 6-modified bicyclic nucleic acid analogs
0
‌
US Patent 7399853 Modulation of glucagon receptor expression
0
‌
US Patent 7425544 Modulation of eIF4E expression
0
‌
US Patent 7427672 Artificial nucleic acids of n-o bond crosslinkage type
0
‌
US Patent 7439043 Galactosyl nucleotide sugars
0
‌
US Patent 7482117 Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
0
...
Patent Primary Examiner
‌
Traviss C Mcintosh, III
0
Patent abstract

Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11851655 Compositions and methods for modulating apolipoprotein (a) expression

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.